Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NOACs

Bristol-Myers Squibb (BMS) building

BMS melanoma combo impresses at ASCO

Increases survival in difficult to treat form of skin cancer

- PMLiVE

Boehringer launches iPhone app for patients on Gilotrif

App offers treatment guide for those taking its cancer drug

Boehringer Ingelheim headquarters

Boehringer bags FDA approval for Spiriva-based combo

Stiolto given the thumbs up as a once-daily maintenance therapy for COPD

- PMLiVE

Boehringer signs digital health collaboration with Sutter Health

Workwill start in COPD with a personalised medical care project

Bristol-Myers Squibb (BMS) building

BMS shines in Q1, but Abilify generics cast a long shadow

Revenue up 6% but Ablify’s contribution likely to drop due to competition

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo backed as melanoma therapy in EU

First checkpoint inhibitor to be recommended for approval in the region

Boehringer Ingelheim headquarters

Boehringer’s sales drop after ‘intense and challenging’ year

US operations hit hard by healthcare reforms and insurance consolidation

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

Boehringer Ingelheim headquarters

Boehringer signs renal disease research collaboration

Will work with Hydra Biosciences to identify small-molecule TRP inhibitors

- PMLiVE

IQWiG passes Boehringer lung cancer drug

Germany’s cost assessor says it can extend life in some patients, but benefit it ‘minor'

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links